EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Editorial: Neuropharmacology of neuro -degenerative, -logical, -psychiatric disorders

Harpreet Kaur

Frontiers in Pharmacology · 13.06.2023 · 14

DOI: 10.3389/fphar.2023.1223200 ↗

Kurz gefasst

Editorial in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.06.2023. Verfasst von Harpreet Kaur. Beteiligte Einrichtung: Center for Neurological Restoration, Neurological Institutes, Cleveland Clinic, Cleveland, OH, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 1 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Editorial on the Research Topic Neuropharmacology of neuro -degenerative, -logical, -psychiatric disordersNeuropsychological disorders are the leading cause of disability worldwide, significantly burdening health and the economy (GBD 2016 Neurology Collaborators, 2019).Despite the extensive clinical and experimental (in-vivo and in-vitro) research to reduce the burden, over the past 25 years, the incidence, prevalence, mortality, and disability rates of neurological disorders have been rising globally.In this Research Topic of Frontiers in Pharmacology on "Neuropharmacology of Neuro -degenerative, -logical, -psychiatric disorders" we received three original articles, one clinical trial, and one review covering recent and exciting findings about the role of the various promising drugs or potential compounds to treat these disorders.Hecker et al. studied multiple sclerosis (MS), a chronic autoimmune disease, and screened three databases named Stockley's, Drugs.com, and MediQ to find potential drug-drug interactions (pDDIs) among MS patients. Total 1,684 pDDIs were identified in 627 patients enrolled in this study, of which 318 pDDIs were common among the three databases. This article reported that 35.2% of the 627 patients had at least one severe pDDI, significantly associated with older age, lower educational level, living without a partner, comorbidities, and the number of medications taken. The author emphasizes addressing pDDIs through improved digital health services and recommends screening multiple databases to find pDDIs (Hecker et al.).Another research article by Zhu et al. addresses structural abnormalities associated with depression using chronic unpredictable stress (CUS) animal model. This study's findings suggest that the liver X receptor agonist, GW3965, improved CUS-induced depressive symptoms, improving understanding of underlying molecular mechanisms and behavioral basis. Further investigations revealed a decreased number of CC1+ oligodendrocytes (OL) and the density of BrdU+/Olig2+/CC1+ cells in each hippocampal subregion of CUS mice. GW3965 treatment in CUS mice increases MBP expression in the CA3 region. These findings indicate that improved OL maturation and enhancement of myelination may be structural mechanisms underlying the antidepressant effects of LXR agonists (Zhu et al.).Li et al. studied the effect of duloxetine on anxiety and pain in complete Freund's adjuvant mice with chronic inflammatory pain.Intraperitoneal injection of duloxetine causes decreased glutamatergic excitability and enhanced serotonin concentration in the anterior cingulate cortex.This study sheds light on the potential mechanism of the anxiolytic

Schlagwörter

Stichwörter der Autor:innen

animal modelbrain disordersclinical researchdrug repositioningdrug toxicity

Autor:innen und Institutionen

  • Center for Neurological Restoration, Neurological Institutes, Cleveland Clinic, Cleveland, OH, United States.

Zitieren

APA

Kaur, H. (2023). Editorial: Neuropharmacology of neuro -degenerative, -logical, -psychiatric disorders. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1223200

Vancouver

Kaur H. Editorial: Neuropharmacology of neuro -degenerative, -logical, -psychiatric disorders. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1223200

BibTeX
@article{Kaur2023,
  author = {Kaur, Harpreet},
  title = {Editorial: Neuropharmacology of neuro -degenerative, -logical, -psychiatric disorders},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1223200}
}
Kostenlos starten →